Rasonque FDA Approval Lifts Revolution Medicines Stock 0.8% at $45.7 Billion Valuation
Rasonque won U.S. approval Wednesday, giving Revolution Medicines, Inc. its first commercial product. The stock rose 0.77% to $213.01 at 11:55 a.m. EDT.
Nvidia Shares Drop 1.8% Following $96.2 Billion Quarterly Revenue, With AI Commitments Now at $366 Billion
SANTA CLARA, California, August 26, 2026, 16:30 EDT — Nvidia stock declined by 1.8% after reporting quarterly revenue of $96.2 billion, as the company’s total AI-related commitments reached $366 billion.
NVIDIA · NASDAQ:NVDA · Q2 FY2027
Revenue beat, balance-sheet test
Market data: Aug. 26, 2026, 16:30 EDT
Financials: quarter ended July 26, 2026
Financials: quarter ended July 26, 2026
After hours
$205.92 · -1.78%
Close $209.66 · about $90B value erased
Q2 revenue
$96.22B
+106% YoY · +4.2% vs FactSet consensus
Q3 outlook
$108.0B
+3.6% vs $104.2B consensus · ±2% range
Commitments + guarantees
$474.5B
8.4× cash and marketable debt securities
Revenue acceleration
Q2 Data Center revenue was $89.0B, or 92.5% of total sales.
Investor bridge
| Measure | Value | Signal |
|---|---|---|
| Adjusted EPS | $2.22 | +6.2% vs est. |
| Q2 gross margin | 75.0% | Flat QoQ |
| Q3 gross margin | 74.0% | -1.0 pt |
| Free cash flow | $21.34B | -56% QoQ |
| DSO | 60 days | +15 days |
Commitment stack
Supply and capacity · $279B
Other contractual commitments · $87B
Contingent guarantees · $108.5B
Supply commitments rose $160B, or 134%, in one quarter. The guarantee total includes $105B for the Ohio site and $3.5B for AI-cloud leases.
Operating signals
| Metric | Q2 FY27 | Sequential | Why it matters |
|---|---|---|---|
| Data Center | $89.0B | +18% | Core demand remains strong |
| ACIE | $40.3B | +25% | Faster than hyperscale |
| Receivables | $63.1B | DSO 45→60 | Cash conversion slowed |
| Inventory | $31.6B | +22% | Rubin launch build |
| Operating cash flow | $24.1B | -52% | Working capital and taxes |
What changes the thesis
Bull: $108B revenue converts to cashBull: ACIE sustains 25% QoQ growthBear: margin falls below 73.5%Bear: DSO extends againBear: customer guarantees activate
Commitments are future obligations, not immediate debt. Guarantees are contingent. The valuation test is whether Nvidia's revenue and free cash flow scale faster than supply, lease and customer-support exposure.
Rasonque approval dashboard
Revolution Medicines moves from trial risk to launch risk
NASDAQ:RVMD · PRODUCT/COMMERCIAL CATALYST
Market data: August 26, 2026
11:55 EDT / 17:55 Europe/Warsaw
11:55 EDT / 17:55 Europe/Warsaw
RVMD price
$213.01
+$1.63 · +0.77%
Market value
$45.65B
≈ $351M added today
Session range
8.3%
$198.91 low · $216.50 high
Volume by 11:55
1.10M
64% of 1.71M daily average
Session price map
Range positions are scaled from the verified session low and high. This is not a minute-by-minute price chart.
What changed
Rasonque is now a first-in-class, once-daily oral RAS inhibitor for certain adults with metastatic pancreatic cancer.
First product revenueNow possible
PricingNot disclosed
AvailabilityNot disclosed
Expanded-access patients2,000+
Phase 3 survival comparison
Rasonque median overall survival13.2 months
Standard chemotherapy6.7 months
Absolute improvement+6.5 months
Relative improvement+97%
Trial population500 adults
Valuation versus operating base
| Metric | Amount | Ratio to market cap |
|---|---|---|
| Quoted market value | $45.65B | 100% |
| Cash and securities, June 30 | $3.94B | 8.6% |
| 2026 operating-expense midpoint | $2.15B | 4.7% |
| Q2 operating expenses | $505.1M | 1.1% |
| Q2 net loss | $644.4M | 1.4% |
Cash equals 1.83× the midpoint of the current annual expense guide. It is not a formal runway estimate.
Analyst expectations
Buy ratings18
Hold ratings1
Average target$222.89
Implied upside4.6%
Target range$179–$291
Based on Google Finance’s 19-analyst, three-month set at the market-data timestamp.
What the valuation requires
Launch pricing and reimbursementNear term
Initial prescriptions and net salesNext reports
First-line pancreatic expansionPhase 3
RAS-mutant lung cancer readoutExpected 2027
Broad peak-sales estimate>$20B
The >$20B estimate assumes success beyond today’s approved patient group; current market value is about 2.3× that figure.
Catalyst timeline
Phase 3 survival data established the approval case.
Company reported U.S. launch readiness and $3.94B liquidity.
FDA approved Rasonque for the initial metastatic setting.
Pricing, availability, reimbursement and prescription uptake.
Risk monitor
Commercial
Pricing remains unknown. Slow coverage decisions can defer revenue even after approval.
Execution
Manufacturing limits or weak real-world uptake would pressure launch estimates.
Valuation
The average analyst target offers only 4.6% upside. Failed expansion trials would narrow the revenue base.
Investor bridge
Approval creates the first direct sales channel for Revolution Medicines. The financial test is whether Rasonque’s launch and later-label expansion can grow into a $45.65 billion valuation while annual operating expenses run near $2.15 billion.
Apple Shares Gain 1.1% as Mac mini M6 Launches with 12.5% Price Increase to $899
Apple's Mac mini featuring the new M6 comes at a steeper price for its compact desktop line. Apple Inc. stock gained 1.1% to $313.37 on Wednesday.
Mac mini with M6 · Apple NASDAQ:AAPL
A 12.5% price test for a record Mac business
Company · Product/commercial catalyst
Market data: August 26, 2026, 11:11:19 EDT
Financials: fiscal Q3 ended June 27, 2026
Financials: fiscal Q3 ended June 27, 2026
AAPL price
$313.37
+$3.47 · +1.12%
Nasdaq real-time, market open
Mac mini M6
$899
+$100 · +12.5%
U.S. starting price versus predecessor
Mac revenue
$10.4B
+28.7% year over year
Record June quarter
Market value
$4.573T
About $50.6B added at 11:11 EDT
The launch connects pricing to local-AI demand
Consumer entryProfessional AI mix
Mac's financial weight
Mac share of Q3 revenue9.5%
Mac year-over-year growth28.7%
$100 price rise / old $799 base12.5%
One point of quarterly Mac growth≈$104M
Latest company signals
| Fiscal Q3 2026 | Value | YoY |
|---|---|---|
| Revenue | $109.4B | +16% |
| Net income | $29.8B | +27% |
| Diluted EPS | $2.02 | +29% |
| Gross margin | 50.1% | +3.6 pts |
| Mac revenue | $10.4B | +28.7% |
Gross margin included an approximately two-point tariff-refund benefit.
Investor transmission map
Higher priceA $100 increase supports revenue per unit.
AI performanceM6 targets local models and always-on agents.
Memory costsComponent inflation can absorb pricing gains.
Unit demandA 12.5% entry-price rise can slow volumes.
Stock and valuation
Session range$308.80–$313.45
Volume at 11:06 EDT7.20M
Average volume55.95M
Trailing P/E35.94×
52-week range$225.95–$344.57
Analyst expectations and next checks
S&P Global consensusBuy
Average target$326.34
Target upside at timestamp4.1%
Estimated earningsOctober 29, 2026
Risks
Apple gives no Mac mini unit or revenue forecast. Higher prices may weaken demand. Memory constraints can delay shipments or pressure margins. Product claims are based on Apple's controlled tests.
Meta Stock Gives Back Most of 4.1% Jump as $10 Billion Charge Lands
Meta Platforms, Inc. shares gave back most of an early 4.1% jump on Wednesday. The stock traded at $573.05, up 0.5%, at 10:09 a.m. EDT.
Meta Platforms · NASDAQ:META
Settlement relief meets a $10 billion charge
Company · Stock move
Market data: August 26, 2026, 10:09:24 EDT
Financials: quarter ended June 30, 2026
Financials: quarter ended June 30, 2026
Share price
$573.05
+$2.99 · +0.53%
Nasdaq real-time, market open
Intraday path
$561.95–$593.27
Opened $590.44; high was +4.07% versus prior close
Volume
12.33M
66.8% of 18.45M average by 10:09 EDT
Market value
$1.46T
Quoted gain near $7.6B at the timestamp
The market repriced the headline twice
Relief at avoided trial exposureCharge and operating terms absorbed
Charge versus Meta's balance sheet
$10B Q3 charge / Q2 net income63.1%
$10B Q3 charge / cash & securities11.1%
$16.68B maximum / Q2 net income105.3%
$16.68B maximum / cash & securities18.5%
Latest operating signals
| Q2 2026 | Value | YoY |
|---|---|---|
| Revenue | $60.80B | +28% |
| Net income | $15.85B | -14% |
| Operating margin | 31% | -12 pts |
| Ad impressions | — | +14% |
| Average ad price | — | +12% |
| Daily active people | 3.60B | +3% |
Investor transmission map
SettlementTrial uncertainty falls; maximum payment becomes measurable.
AccountingAbout $10B hits Q3 legal expense and GAAP earnings.
Product controlsTeen time limits and overnight blocks can reduce engagement.
AdvertisingLower engagement can reach impressions, price and Family of Apps revenue.
Valuation and expectations
TTM P/E21.54×
Forward P/E at $573.0518.4×
2026 consensus EPS$31.16
Average analyst target$754.84
Implied target upside31.7%
Ratings47 strong buy · 8 buy · 7 hold
What to watch next
Q3 revenue guidance$61B–$64B
2026 capex guidance$130B–$145B
Estimated Q3 reportOctober 28, 2026
Risks
Court approval, payment timing and the conditional $5.3B remain unresolved. Meta faces thousands of related cases. Teen protections could affect engagement and advertising economics. The charge may force a revised expense outlook.
The Witcher 3 Remastered Is Free; CD Projekt Shares Slip 0.8% on Heavy Volume
The Witcher 3: Wild Hunt — Remastered gives CD Projekt S.A. a low-price acquisition tool for its 2027 paid expansion. The upgrade is free for existing owners, but opens two new storefronts and refreshes a game with 65 million lifetime sales.
WSE: CDR · Product catalyst
The Witcher 3: Wild Hunt — Remastered
A free September upgrade expands the funnel for a paid 2027 expansion.
Market snapshot
Aug. 26, 2026 · 15:23:28 CEST
Aug. 26, 2026 · 15:23:28 CEST
Share price
240.90 zł
−0.82% · −2.00 zł
Range 240.00–246.70 zł
Trading activity
395.85K
1.39× average daily volume
Average: 285.26K shares
Installed base
65M+
Lifetime Witcher 3 copies sold
Analyst case
70–75M
Potential base before 2027 expansion
From free upgrade to paid-content revenue
Sept. 29
Free remaster
Free remaster
→
New reach
Switch 2 + Battle.net
Switch 2 + Battle.net
→
2027
Paid Songs of the Past
Paid Songs of the Past
Launch facts
Gamescom reveal and trailer.
Original expansions become free for existing owners.
Remaster launches; new native Switch 2 and Battle.net editions.
Paid Songs of the Past expansion.
Q1 2026 economics
| Metric | Value | YoY |
|---|---|---|
| Group revenue | 191.1M zł | +6% |
| Witcher IP revenue | 44.7M zł | +36% |
| Witcher share of sales | 23.4% | +5.2 pts |
| Net profit | 106.2M zł | −5% |
| Cash/deposits/bonds | 1.41B zł | +6% q/q |
Stock and valuation
| Signal | Reading |
|---|---|
| Market cap | 24.01B zł |
| Quoted value lost today | ≈199.8M zł |
| Trailing P/E | 39.41× |
| 52-week range | 211.30–297.00 zł |
| Shares outstanding | 99.91M |
| Erste view | Meaningful positive Q4 impact |
Investor interpretation
| Driver | Upside | Constraint |
|---|---|---|
| Free remaster | Reactivates a 65M-player catalogue | No upgrade revenue from existing owners |
| New platforms | Incremental unit sales and distribution | Platform royalties and launch costs |
| Paid 2027 expansion | Monetizes a larger installed base | Pricing and release date undisclosed |
| 2028 Witcher 4 target | Extends franchise roadmap | Long flagship-release gap |
Risk check
The 70–75 million-copy figure is an analyst estimate. A free update can lift engagement without converting into enough new purchases or expansion sales.
Attention signal
Google Trend: “the witcher 3 wild hunt remastered” · Canada, active at selection; trading volume already above average.
Sources: CD Projekt announcement and Q1 2026 presentation; Reuters, Aug. 26, 2026; Google Finance at 15:23:28 CEST. Time-sensitive figures are timestamped above.
Boston Scientific Shares Drop 4.1% After Cyberattack Threatens Up to $369 Million in Q3 Revenue
NEW YORK, August 26, 2026, 09:40 – Shares of Boston Scientific fell 4.1% after the company disclosed that a cyberattack may endanger as much as $369 million in third-quarter sales.
NYSE: BSX · Cyberattack monitor
Boston Scientific
Order-processing and shipment disruption meets a reduced 2026 growth outlook.
Market snapshot
Aug. 26, 2026 · 09:40:21 EDT
Aug. 26, 2026 · 09:40:21 EDT
Share price
$47.81
−4.11% · −$2.05
Open $47.00 · range $46.90–$48.53
Quoted value lost
$2.97B
Estimated from 1.45B shares outstanding
Q3 revenue guide
$5.22–$5.32B
3%–5% growth vs. Q3 2025
Revenue risk scenario
$316–$369M
Evercore: 600–700 bp if recovery mirrors Stryker
Market repricing versus modeled sales exposure
The stock-market loss equals roughly 8.0×–9.4× the analyst's modeled revenue exposure.
Market valueLow scenarioHigh scenario
What moved the stock
Company detects a cybersecurity incident.
Discloses global disruption, including systems that process and ship orders.
Shares open at $47.00, 5.74% below prior close.
BSX trades at $47.81, down 4.11%.
Operating base
| Metric | Q2 2026 | YoY |
|---|---|---|
| Total sales | $5.442B | +7.5% |
| Cardiovascular | $3.624B | +8.3% |
| MedSurg | $1.818B | +5.9% |
| Adjusted EPS | $0.86 | +14.7% |
| GAAP net income | $907M | +13.8% |
Guidance and valuation
| Signal | Current reading |
|---|---|
| FY26 sales growth | 5.5%–6.5% reported |
| FY26 adjusted EPS | $3.28–$3.32 |
| Q3 adjusted EPS | $0.80–$0.82 |
| P/E | 19.38× |
| Analyst consensus | Buy · 31 analysts |
| Average target | $62.69 · 31% upside |
Scenario frame
| Recovery path | Revenue effect | Investor implication |
|---|---|---|
| Faster than Stryker | Below $316M | More orders may shift within the quarter rather than disappear. |
| About three weeks | $316M–$369M | Evercore's 600–700 bp scenario; a guide cut becomes plausible. |
| Longer or broader | Above $369M | Margin pressure and customer disruption could outlast shipment delays. |
Risk check
Boston Scientific has not determined whether the incident is reasonably likely to be material. The full scope, recovery duration and any data loss remain unknown.
Watch next: recovery timetable, shipment resumption, order recapture, guidance update.
Sources: Boston Scientific Q2 2026 results; Reuters, Aug. 26, 2026; Google Finance quote at 09:40:21 EDT; StockAnalysis analyst consensus. The $316M–$369M range is a scenario calculation, not company guidance.
Callaway Golf shares slip 2% amid $430 million equipment division’s exposure to Quantum Driver ad campaign
CARLSBAD, California, August 26, 2026, 05:45 – Callaway Golf stock declined 2% on Wednesday following market reaction to ad pull testing related to its Quantum Driver, putting the company’s $430 million equipment segment under pressure.
Callaway Golf Company · NYSE:CALY
Quantum campaign fallout
A compact view of the stock reaction, the $699.99 co-branded driver, and the equipment segment carrying most of Callaway's quarterly revenue.
Market data: Aug. 26, 2026, 08:21:15 EDT
Financials: quarter ended Jun. 30, 2026
Financials: quarter ended Jun. 30, 2026
Aug. 25 close
$15.47
−2.03% · −$0.32
Official close, 16:00:03 EDT
Premarket
$15.56
+0.58% · +$0.09
Aug. 26, 08:21:15 EDT
Volume
1.27M
59% of 2.14M average
Aug. 25 session
Market value
$2.78B
Est. $57.1M erased
32¢ × 178.51M shares
Investor bridge: market loss versus equipment economics
Product and catalyst
Limited driver
$699.99
Good Good Quantum Triple Diamond Max, 460cc head, adjustable 10g weight.
Ad withdrawnCEO apologyTwo investigationsApproval changes
Golf Equipment — Q2 2026
| Metric | Result |
|---|---|
| Revenue | $430.3M · +4.5% |
| Operating income | $100.3M · +31.6% |
| Operating margin | 23.3% · +480 bp |
| Share of group sales | 70.3% |
Group signals
| Metric | Result |
|---|---|
| Q2 sales | $612.2M · +2.0% |
| GAAP gross margin | 50.1% · +620 bp |
| FY26 sales guide | $2.045B–$2.070B |
| FY26 adjusted EBITDA | $246M–$260M |
Analyst expectations
Consensus
Buy
| Average target | $20.50 |
| Implied upside from $15.47 | 32.5% |
| Coverage | 11 analysts |
| Rating mix | 5 Strong Buy · 5 Hold · 1 Sell |
S&P Global consensus, accessed Aug. 26, 2026.
Catalyst timeline
Aug. 21Good Good posts the co-branded driver video; it is removed within hours.
Aug. 22Good Good and Callaway issue preliminary responses.
Aug. 25Chip Brewer accepts Callaway's approval role and announces internal and external reviews.
Next evidenceProduct availability, partner actions and Callaway's next sales update.
What can change the thesis
Contained case: investigations close without retailer, media or partner withdrawals; the 0.58% premarket rebound persists. Adverse case: partner action raises campaign costs or weakens demand in a segment producing 70.3% of quarterly sales. Watch the product listing, PGA Tour decisions and management's next equipment-sales commentary.
Marvell Shares Rise 4.8% Ahead of Key $120 Billion Google Revenue Earnings Report
Marvell Technology, Inc. rose 4.84% to $240.38 on Tuesday. Price targets were increased by Susquehanna and Rosenblatt ahead of the company’s earnings scheduled for Thursday. In delayed premarket trade at 05:01 EDT, shares were up 0.20% at $240.85.
Marvell: the $120 billion revenue test
A 4.84% rally prices faster AI growth before Thursday's earnings.
Aug. 25 close
$240.38
+$11.09 · +4.84%
NASDAQ close, Aug. 25, 2026, 16:00 EDT
Premarket
$240.85
+0.20%
Delayed quote, Aug. 26, 2026, 05:01 EDT
Market value
$210.52B
Tuesday added about $9.7B
MarketWatch, Aug. 25 close
Volume
21.35M
53% of 65-day average
Aug. 25 regular session
What Google must buy for full performance vesting
240purchase-based tranches
$500Mrevenue per tranche
$120Btotal qualifying revenue
14.6×Marvell FY2026 revenue
The purchases are discretionary. The $120 billion figure is a warrant-vesting ceiling, not booked revenue or guidance.
Fresh analyst targets
Targets: $265, $267.82 and $300. The consensus covers 44 analysts and carries a Strong Buy rating.
Earnings move priced by options
A 10% move equals roughly $21 billion of market value, or 7.8 times the Q2 revenue guide.
Operating baseline
| Measure | Latest |
|---|---|
| Q1 FY2027 revenue | $2.418B · +28% |
| Data Center revenue | $1.83B · +27% |
| Data Center share | 76% |
| Non-GAAP gross margin | 58.9% |
| Operating cash flow | $638.8M |
| Q2 revenue guide | $2.70B ±5% |
| Q2 adjusted EPS guide | $0.93 ±$0.05 |
Warrant economics
| Term | Figure |
|---|---|
| Maximum warrant shares | 58.97M |
| Exercise price | $206.58 |
| Discount to Aug. 25 close | 14.1% |
| Potential gross proceeds | $12.18B |
| Current-share equivalent | 6.7% |
| Purchase vesting window | FYQ3 2027–FY2033 |
| Average annual threshold | About $18.5B |
Risks and dated checkpoints
Revenue is conditional
Slower Google purchases reduce vesting and delay the expected sales ramp.
Slower Google purchases reduce vesting and delay the expected sales ramp.
Dilution matters
Full exercise equals about 6.7% of current shares, offset partly by $12.18 billion of proceeds.
Full exercise equals about 6.7% of current shares, offset partly by $12.18 billion of proceeds.
Valuation is stretched
MRVL is up 182.9% this year and trades near 82 times trailing earnings.
MRVL is up 182.9% this year and trades near 82 times trailing earnings.
Next checkpoint
Results follow Thursday's close; management's call begins Aug. 27 at 16:45 EDT.
Results follow Thursday's close; management's call begins Aug. 27 at 16:45 EDT.
Sources: market dataGoogle agreement 8-KQ1 resultsanalyst consensusearnings schedule. Calculations use company filings and the Aug. 25 close.
Take-Two Faces $8.2 Billion Revenue Test with GTA 6 Netflix Launch
NEW YORK, August 26, 2026, 05:20 EDT — Take-Two Interactive’s projected $8.2 billion in bookings comes into focus as the gaming giant prepares for the Netflix premiere of Grand Theft Auto 6, a major release the company hopes will reinforce its revenue outlook.
Product catalyst · Investor dashboard
GTA VI’s Netflix preview meets Take-Two’s bookings test
A six-hour streaming exclusive concentrates attention before the November launch. The financial question is conversion, not trailer views.
Market data: Aug. 25, 2026, 16:00 EDT
Prepared: Aug. 26, 2026, 05:20 EDT
Prepared: Aug. 26, 2026, 05:20 EDT
TTWO close
$232.93
−0.24%
Aug. 25 regular session
After hours
$233.58
+0.28%
Latest verified quote: 16:54 EDT
Equity value
$43.55B
Approximate market capitalization
Netflix head start
6 hours
3 p.m. to 9 p.m. EDT, Aug. 27
The event
Grand Theft Auto VI: An Extended Look premieres to Netflix members at 3 p.m. EDT Thursday.
Public release9 p.m. EDT · YouTube + GTA VI site
Game launchNov. 19, 2026
Standard / Ultimate$79.99 / $99.99
Edition premium25.0%
Fiscal 2027 bookings bridge
Q1 bookings$1.39B
Full-year guidance$8.0B–$8.2B
Still required after Q1$6.61B–$6.81B
Q1 equals 17.2% of the $8.1B guidance midpoint. GTA VI launches during the fiscal year.
Price position inside 52-week range
The average analyst target sits above the current 52-week high. That requires execution beyond a successful marketing event.
Franchise scale
470M+
Grand Theft Auto units sold-in worldwide
GTA V alone230M+
Preorders“Unprecedented”
Published unitsNot disclosed
Illustrative launch spending
| Units | Standard | Ultimate |
|---|---|---|
| 10M | $0.80B | $1.00B |
| 25M | $2.00B | $2.50B |
| 50M | $4.00B | $5.00B |
Gross consumer spending before platform fees, tax, refunds and edition mix. Not company guidance.
Analyst expectations
Strong Buy| Buy / Hold / Sell | 27 / 0 / 1 |
| Average target | $286.89 |
| Implied upside | 23.2% |
| Low / High | $170 / $368 |
Why investors care
Take-Two needs a sales curve, not merely a cultural moment.
Preview qualityA weak showcase may slow preorder momentum.
ConversionSix hours of exclusivity may not produce measurable subscriptions.
ScheduleAnother delay would push bookings and cash flow outward.
VisibilityPreorder units remain undisclosed and cancellable.
Sources: Take-Two investor relations and preorder release; Netflix Tudum; Reuters; StockAnalysis; Investing.com. Scenario calculations are illustrative. Prices are in U.S. dollars.
CRISPR Therapeutics Stock Rises 6.7% Before CTX310 Data as $80 Target Signals 31% Upside
CRISPR Therapeutics AG rose 6.70% before a late-breaking CTX310 presentation. The stock closed Tuesday at $60.90. Volume reached 2.08 million shares.
NASDAQ: CRSP · CTX310 event monitor
CRISPR Therapeutics
Investors paid for clinical optionality before the August 28 durability update.
U.S. market closedClose: Aug. 25, 2026, 16:00 EDT
After hours: $60.77, −0.21% at 17:01 EDT
After hours: $60.77, −0.21% at 17:01 EDT
Close
$60.90
Aug. 25, 16:00 EDT
Daily move
+6.70%
+$3.83 per share
Quoted value added
≈$370M
Estimate using ≈96.7M shares
Volume
2.08M
1.24× 1.69M average
Market value
$5.89B
At Aug. 25 close
Seven-session price path
Daily closes, Aug. 17–25, 2026. The latest move recaptured the prior week's high.
What moved: Citizens reiterated Market Outperform and an $80 target before the CTX310 late-breaking presentation. The target stood 31.4% above Tuesday's close.
Catalyst clock
The valuation test shifts from anticipation to durability.
Citizens kept an $80 target. CRSP closed 6.70% higher on 1.24× average volume.
Late-breaking ESC presentation. The scheduled 10:30 EDT session covers Phase 1a CTX310 durability.
Management expects another CTX310 update as Phase 1b evaluates additional patients and dose selection.
The key question
Can one-time ANGPTL3 editing preserve lipid reductions without new safety signals? Durable effects would strengthen the cardiovascular-platform case. Short-lived effects would weaken it.
CTX310 efficacy seen so far
Mean reductions at the highest tested dose in initial Phase 1 data; investigational treatment, not an approved product.
Maximum individual reductions were 89%, 84% and 87%, respectively. Initial analysis covered 15 participants with average follow-up of at least 60 days. No treatment-related serious adverse events or grade 3-or-higher liver-transaminase changes were reported.
Balance-sheet buffer
Reported for the quarter ended June 30, 2026.
Cash + securities$2.36B40.1% of market value
Q2 net loss$91.2MGAAP
Simple runway≈26 qtrsCash ÷ one quarter's loss
Q2 revenue$10.2MCollaboration revenue
R&D$67.2MQ2 expense
Convertible proceeds$585.4MIncluded in liquidity build
The 26-quarter figure is a mechanical ratio, not management guidance. Clinical spending, milestones and working capital will change the actual runway.
Analyst valuation range
Targets available Aug. 25, 2026; upside or downside versus the $60.90 close.
| Reference | Target | Implied move |
|---|---|---|
| Citizens | $80.00 | +31.4% |
| S&P Global average | $87.56 | +43.8% |
| S&P Global median | $80.00 | +31.4% |
| S&P Global low | $44.00 | −27.8% |
BUY S&P Global consensus across 22 analysts. Targets are opinions, not forecasts.
Commercial anchor: CASGEVY
Vertex leads commercialization; economics are shared with CRISPR Therapeutics.
Q2 revenue$76MReported by Vertex
Sequential growth+78%Quarter over quarter
Annual growth+151%Year over year
Vertex and CRISPR Therapeutics share CASGEVY profits and costs 60%/40%. The approved therapy provides commercial validation, but CTX310 has a different delivery method, target and risk profile.
Risk monitor
The stock move came before detailed durability data.
- CTX310 remains in early clinical development and generates no product revenue.
- The initial sample was small. Longer follow-up could change efficacy or safety conclusions.
- Durability, dose selection, liver safety and off-target editing remain central clinical tests.
- Convertible financing supports cash runway but can create interest expense and future dilution.
- CASGEVY uptake does not guarantee success for an in-vivo cardiovascular program.
Boeing Stock Gains 0.3% as $131 Billion F-15 Ceiling Starts With $344,000
The Boeing Company shares ended 0.29% higher Tuesday after the U.S. Air Force awarded Boeing a ceiling contract worth $131.23 billion for its F-15 Eagle Crest program. The stock closed at $211.08, then added 0.08% after hours.
Boeing · NYSE:BA · F-15 Eagle Crest
The $131.23B ceiling starts with $343,740
Checked Aug. 26, 2026
04:52 EDT · U.S. premarket
04:52 EDT · U.S. premarket
Aug. 25 close
$211.08
+0.29% · after hours $211.25
Market value
$166.83B
About +$490M Tuesday
Volume
4.85M
82% of 65-day average
Analyst consensus
Moderate Buy
22 analysts · $272.58 average target
Contract scale versus booked business
Ceiling / backlog1.54×Capacity comparison, not booked sales
Ceiling / Q2 BDS revenue17.5×Equivalent quarterly scale
Performance horizon2037Orders through 2031; option to 2036
Defense economics
| Q2 BDS revenue | $7.483B | +13% YoY |
| Q2 BDS operating margin | -0.2% | -1.9 pts YoY |
| BDS backlog | $85B | 27% international |
| Company cash + securities | $20.0B | Q2 end |
| Consolidated debt | $45.9B | Q2 end |
| VC-25B Q2 loss charge | $280M | Margin warning |
Latest defense-stock tape
| Company | Latest price | Move | Market cap | P/E |
|---|---|---|---|---|
| Boeing (BA) | $211.08 | +0.29% | $166.83B | 96.1× |
| Lockheed Martin (LMT) | $556.52 | -1.35% | $128.44B | 20.5× |
| General Dynamics (GD) | $376.58 | -1.88% | $101.89B | 23.0× |
| Northrop Grumman (NOC) | $542.52 | -1.24% | $77.25B | 17.3× |
Latest feed values checked Aug. 26 at 04:39 EDT; BA close and after-hours data are timestamped Aug. 25. Peer feeds may reflect their latest available extended-hours print.
What turns ceiling into cash
Aug. 24, 2026$131.23B ceiling awarded; $343,740 obligated
Through Aug. 2031Base ordering period for funded task orders
Option to Aug. 2036Government may extend ordering window
By Aug. 2037Expected completion horizon
Investor testOrders × margin × timingWatch funded task-order values, backlog recognition, supplier costs and BDS operating margin. A large ceiling alone does not guarantee revenue.
Valuation and next catalysts
Average target$272.5829.1% above Aug. 25 close
Target range$223–$305Current 22-analyst aggregation
Next earningsOct. 28Q3 2026: backlog, cash flow and BDS margin
Sources: U.S. contract notice dated Aug. 24, Boeing Q2 results dated July 28, WSJ market data, MarketBeat analyst aggregation and latest market feeds. Ratios are calculated from displayed inputs. Ceiling value is not guaranteed revenue or backlog.
Super Micro Shares Rise 9.35% After Cisco Announces October AI Factory Channel Launch
Super Micro Computer, Inc. gained 9.35% after Cisco launched an enterprise channel for its AI servers. Shares ended Tuesday at $38.46. Trading volume was 48.2 million shares.
Super Micro Computer · NASDAQ: SMCI
Cisco channel turns rack-scale AI demand into a margin test
Cisco begins offering Supermicro compute inside Secure AI Factory with NVIDIA in October 2026.
Market data: Aug. 25, 2026, 16:00 EDT
After-hours: 19:59 EDT
After-hours: 19:59 EDT
Close
$38.46
+$3.29 · +9.35%
Quoted value added
$2.13B
646.87M shares × $3.29
Trading activity
47.6M
Aug. 25 volume; 48.2M from consolidated snapshot
After-hours
$38.58
+0.30%
Seven-session price path
CloseObserved session
Quarterly operating pulse
| FY26 | Revenue | Gross margin | Net income |
|---|---|---|---|
| Q1 | $5.0B | 9.3% | $168M |
| Q2 | $12.7B | 6.3% | $401M |
| Q3 | $10.2B | 9.9% | $483M |
| Q4 | $11.1B | 17.5% | $1.18B |
Company-reported GAAP data; fiscal year ended June 30, 2026.
Guidance and balance-sheet signals
FY27 revenue guide$65B–$72B
Midpoint growth vs. FY26+75%
Q1 FY27 revenue guide$14.5B–$15.5B
FY26 cash$7.5B
Bank debt + convertibles$8.7B
Q4 operating cash flow$747M
AI infrastructure read-through · Aug. 25 close, 16:00 EDT
| Company | Close | Daily move | Signal |
|---|---|---|---|
| Super Micro (SMCI) | $38.46 | +9.35% | Cisco channel |
| Dell (DELL) | $451.50 | +4.23% | Server peer |
| HPE (HPE) | $53.44 | +1.93% | Server peer |
| Cisco (CSCO) | $111.11 | +0.80% | Platform owner |
Catalyst clock
AUG 11
Fiscal Q4 results17.5% gross margin; FY27 revenue guide reaches $72B.
AUG 25
Cisco partnershipRack-scale liquid- and air-cooled compute enters Secure AI Factory.
OCTOBER
Commercial availabilityFirst announced month for Cisco to offer Supermicro systems.
Investor takeaway
The Cisco channel validates Supermicro’s rack-scale position, but Tuesday’s $2.13B value gain arrived before any disclosed orders.
The clean confirmation would be sustained enterprise revenue plus gross margin near Q4’s 17.5%, rather than a return toward the 6%–10% range seen earlier in fiscal 2026.
The clean confirmation would be sustained enterprise revenue plus gross margin near Q4’s 17.5%, rather than a return toward the 6%–10% range seen earlier in fiscal 2026.
Moderna Shares Surge 14.4% After Cancer-Vaccine Repricing Boosts Valuation by $8 Billion
Moderna Inc. surged 14.36% on Tuesday to close at $158.83 after Wolfe Research raised its rating on the stock to Peer Perform from Underperform. The $19.94 increase boosted Moderna's quoted equity value by approximately $8.0 billion.
Moderna · NASDAQ:MRNA
Cancer-vaccine repricing dashboard
Stock move, valuation, trial evidence and cash runway
Market closed · Aug. 25, 2026, 16:00 EDT
Close
$158.83
Aug. 25, 2026, 16:00 EDT
One-day move
+14.36%
+$19.94 per share
Volume
49.05M
3.7× three-month average
Quoted market value
$63.41B
Aug. 25 close
Six-session price path
+152.3% vs. Aug. 18Daily close, EDTSource: market history through Aug. 25, 2026
Valuation bridge
Post-readoutMarket value added Aug. 25≈$8.0B
Market value added vs. Aug. 18≈$38.3B
Q2 2026 revenue$145M
Q2 2026 net loss-$782M
Cash and investments, June 30$6.9B
2026 year-end cash outlook$4.7B–$5.2B
Financial figures reported July 31, 2026. A $950M settlement payment followed in July.
Analyst expectations
Updated through Aug. 25S&P Global consensus: Hold, 23 analysts; average target implies 37.2% downside from Tuesday's close.
Catalyst timeline
Next evidence mattersAug. 19
Phase 3 INTerpath-001 met recurrence-free and distant-metastasis-free survival endpoints; detailed figures withheld.
Aug. 24
Barclays raised its target to $125 from $48 and kept Equal Weight.
Aug. 25
Wolfe Research upgraded MRNA to Peer Perform; shares closed 14.36% higher.
Next
Full Phase 3 presentation, regulator discussions and continued overall-survival follow-up.
Trial and peer context
Aug. 19 catalyst| Measure | Reading | Investor meaning |
|---|---|---|
| INTerpath-001 enrollment | 1,137 patients | First positive Phase 3 individualized mRNA cancer-therapy readout |
| Treatment design | Up to 34 neoantigens; nine intismeran doses | Patient-specific manufacturing adds cost and turnaround risk |
| Phase 2b five-year result | 49% lower recurrence/death risk; 59% lower distant-metastasis/death risk | Supports mechanism, but Phase 3 effect size remains undisclosed |
| Moderna reaction | +176.97% on Aug. 19 | Largest direct platform repricing |
| Merck reaction | +12.6% on Aug. 19 | Extends the Keytruda franchise opportunity |
| BioNTech reaction | about +22% on Aug. 19 | Read-through for personalized mRNA oncology |
Investor bridge
The August 25 rally added about $8.0 billion in value. Since the pre-readout close, the gain is about $38.3 billion. That premium now depends on regulatory timing, manufacturing economics and success beyond melanoma.
Risks
Hazard ratios, absolute event rates and overall-survival data are pending. Personalized production may constrain margins. Other tumors may not reproduce the melanoma result. Cash burn remains material.
Timestamp: Aug. 26, 2026, 03:07 EDT / 09:07 CESTReuters market closeTrial releaseTreatment economicsModerna Q2Analyst consensus
Rezolve AI Shares Surge 21.8% After Google Cloud Web3 Rollout Delivers $211 Million Boost
Rezolve AI PLC climbed 21.81% on Tuesday following the adoption of its distributed database technology by Google. The stock ended the session at $2.96, increasing its quoted equity value by roughly $211 million.
NASDAQ:RZLV • post-close
Google Cloud validation meets a revenue test
Market data: August 25, 2026, 4:00 p.m. EDT
After-hours: 7:59 p.m. EDT • Dashboard: August 26, 2026, 01:10 EDT
Close
$2.96
+21.81% • +$0.53
After-hours
$2.91
−1.68% from close
Volume
98.4M
7.7× 12.9M 3-month average
Market value
$1.18B
≈$211M added Tuesday
Price move and range
The close remains 65.0% below the 52-week high despite Tuesday’s surge.
Catalyst: what is measurable
Initial data footprint100 TB
Blockchain networks10
Checks per block6 + validation
Contract valueNot disclosed
Rezolve says its database provides indexing and pipelines behind Google Cloud Web3 datasets.
Revenue bridge
FY 2025 audited revenuebase$46.8M
H1 2026 preliminaryunaudited≈$127M
FY 2026 guidancetarget≈$360M
Implied H2 requirementderived≈$233M
Preliminary H1 covers 35.3% of guidance. H2 must run about 83% above H1.
Valuation checkpoints
| Measure | Numerator | Denominator | Multiple |
|---|---|---|---|
| Market cap / FY 2025 revenue | $1.18B | $46.8M | 25.2× |
| Market cap / FY 2026 guidance | $1.18B | $360M | 3.3× |
| Tuesday value gain / FY26 guide | ≈$211M | $360M | 0.59× |
| Analyst target / close | $10.50 avg. | $2.96 | 3.55× |
Five-analyst consensus: Strong Buy; target range $7–$15. Targets predate this catalyst.
Financial signals and next catalyst
2025 GAAP gross marginreported66%
2025 net lossreported$101.4M
Year-end cash / operating cash use2025$111.1M / $63.1M
Current vs. year-end sharesdilution398.8M vs. 336.3M
Next confirmed catalystcalendarH1 results • Sep. 1, 8:30 a.m. EDT
Investor read: Google validates the technology, but September must validate economics. Watch recognized revenue, gross margin, cash conversion, outstanding shares and continued support for the $360 million outlook.
Sources: Rezolve AI investor releases dated July 27, August 6 and August 25, 2026; Rezolve AI 2025 Form 20-F; S&P Global Market Intelligence and Nasdaq UTP data displayed by StockAnalysis. Derived figures may differ due to rounding.
Nvidia Shares Gain 2.2% as Options Market Prices in $280 Billion Earnings Move
SANTA CLARA, California, August 25, 2026, 20:45 EDT — Nvidia stock advanced 2.2%, while options traders positioned for a $280 billion change in market value tied to the company's earnings report.
NASDAQ: NVDA · Earnings setup
Nvidia's $280 billion decision point
Market data: August 25, 2026 close, 16:00 EDT
Dashboard updated: August 25, 2026, 20:45 EDT
Dashboard updated: August 25, 2026, 20:45 EDT
Closing price
$213.05
+2.19% Tuesday
Volume
121.8M
shares traded
Implied move
5.4%
about ±$11.50
Equity swing
$280B
options estimate
Market value
$5.16T
about 24.22B shares
Options-defined price envelope
$201.55 downside$224.55 upside
The 5.4% move equals about $11.50 per share. It is an options estimate, not a forecast or a guaranteed trading range.
Confirmed catalyst
26AUG
Fiscal Q2 FY27 results
17:00 EDT · 14:00 PDT
Conference call and webcast
How much movement is priced?
At Tuesday's close, the 7.4% historical response equals about ±$15.77 and roughly $382 billion of equity value.
Investor bridge
3.1×
The $280 billion implied equity swing is roughly 3.1 times Nvidia's $91 billion quarterly revenue guide.
A modest change in revenue growth or margin expectations can therefore move more value than several quarters of sales.
Operating benchmarks
| Metric | Reference |
|---|---|
| Q1 revenue | $81.6B |
| Year-over-year growth | 85% |
| Data Center revenue | $75.2B |
| Data Center growth | 92% |
| Q2 revenue guide | $91.0B ±2% |
| Q2 non-GAAP margin | 75.0% ±0.5 pt |
Analyst expectations
Strong Buy
62 analysts · S&P Global
49 Strong Buy · 10 Buy · 2 Hold · 1 Strong Sell
| Average target | $304.73 |
| Target range | $180–$500 |
| Forward P/E | 20.77 |
What can break the range?
- Revenue: guidance below the $91 billion reference.
- Margins: pressure below the 74.5% low end.
- Demand: softer hyperscaler capital spending.
- China: any change to the zero-compute-revenue assumption.
- Volatility: an actual move closer to the 7.4% history.
Sources: Nvidia investor relations, Reuters options-market reporting, StockAnalysis and S&P Global analyst data. Calculations use the August 25 close of $213.05 and approximately 24.22 billion shares. Figures may not sum because of rounding.
Hyperscale Data Shares Slide 17.3% After 1-for-5 Split Pushes GPU Price Under $1
Shares of Hyperscale Data, Inc. declined 17.33% to $0.3869 on Tuesday, following a 1-for-5 reverse stock split in its debut session post-split.
NYSE American: GPUS · post-split monitor
Hyperscale Data
The reverse split changed the share count, not the economics. The first adjusted close remained deeply below the exchange's $1 reference level.
Market close
Aug. 25, 2026 · 16:00 EDT
22:00 CEST
Aug. 25, 2026 · 16:00 EDT
22:00 CEST
Adjusted close
$0.3869
Yahoo Finance, Aug. 25 close
Session move
−17.33%
First split-adjusted session
Distance to $1
−61.31%
A 158.5% gain is needed to reach $1
Split ratio
1-for-5
Effective Aug. 24 at 23:59 EDT
What the split changed
Class A before679.91Mshares, approximately
÷ 5 →
Class A after135.98Mshares, approximately
Class B changed from roughly 23.88 million to 4.78 million shares. Options and warrants were adjusted proportionally; par value was unchanged.
Intraday stress
Volume reached 24.31 million shares by 15:23 EDT on Aug. 25. The reference close was $0.468 on a split-adjusted basis.
Equity value versus Bitcoin treasury
Estimated Class A values use approximately 135.98 million post-split shares. The Aug. 25 decline erased about $11.0 million. The treasury held 278.0314 bitcoin worth about $21.6 million on Aug. 23.
Operating picture
| Metric | Latest period | Reading | Investor signal |
|---|---|---|---|
| Revenue | Q2 2026 | $34.841M | +34.8% YoY |
| Gross profit | Q2 2026 | about $8.8M | roughly 25% margin |
| Net loss attributable to common | Q2 2026 | −$21.654M | 62.2% of revenue |
| Operating cash flow | H1 2026 | −$9.885M | cash-consuming |
| Cash and equivalents | June 30, 2026 | about $36.8M | below planned campus funding need |
Michigan campus: the operating option
- A customer commitment covers an initial 20 megawatts.
- The Dowagiac site could expand toward 340 megawatts.
- Management estimates more than $100 million of capital is required.
- The latest filing says current liquidity is insufficient for the next 12 months.
No reliable current sell-side consensus price target was available at publication.
Risk register
- Listing: a reverse split does not itself restore a durable price above $1.
- Funding: campus expansion may require new debt, asset sales or dilution.
- Bitcoin: treasury value introduces another volatile balance-sheet variable.
- Execution: the 340-megawatt case depends on financing, construction and customer conversion.
Next investor checks
- Whether GPUS can sustain a bid near the adjusted reference price.
- Financing terms for the Michigan expansion and their share-count effect.
- Named customer additions beyond the initial 20-megawatt commitment.
- Weekly Bitcoin purchases, sales and value per common share.
Oklo Shares Climb 11.5% After Canada Uranium Warning Lifts Value by $850 Million
Shares of Oklo Inc. rose 11.5% on Tuesday, as renewed U.S.-Canada trade friction renewed concerns over uranium supply, impacting advanced-nuclear stocks. Oklo finished the session at $44.26, an increase of $4.57.
OKLO · Nuclear deployment dashboard
Trade risk added $850M in one session
Market close · August 25, 2026 · 16:00 EDT
Ontario named uranium as possible trade leverage. Oklo rallied, though no cutoff or new Oklo contract was announced.
Close
$44.26
+$4.57 Tuesday
One-day move
+11.51%
Regular session
Volume
11.93M
1.11× recent average
Market value
$8.23B
Estimated daily gain: $850M
What the market repriced
The session's added value equaled 6.7× Oklo's $126.9M first-half capital spending. That is a sentiment move, not realized cash flow.
Capital runway vs. build-out
| Metric | Amount |
|---|---|
| Cash + marketable securities | $3.01B |
| H1 ATM equity proceeds | $1.85B |
| H1 operating cash use | $65.5M |
| H1 capital spending | $126.9M |
| 2026 operating cash-use guide | $120–150M |
| 2026 PP&E guide | $400–500M |
Balance-sheet figures through June 30, 2026. Source: Oklo Form 10-Q and Q2 call.
Analyst valuation map
| Measure | Target / view |
|---|---|
| Consensus | Buy · 15/9/1 |
| Average target | $79.88 · +80% |
| Median target | $81.50 · +84% |
| Truist | Hold · $51 |
| H.C. Wainwright | Buy · $90 |
| Canaccord | Buy · $100 |
Latest compiled targets available August 25; recent firm calls dated August 10.
Investor transmission
AUG 24Ontario warns that uranium and other exports could be used as leverage.
AUG 25Canada announces retaliatory tariffs; no uranium cutoff is ordered.
AUG 25 CLOSEOKLO finishes up 11.5%, adding about $850M in value.
NEXT CHECKWatch formal supply policy, fuel agreements and deployment milestones.
Policy riskHALEU accessGroves executionAurora scheduleEquity dilution
Investment read-through
Oklo has enough liquidity to fund near-term work, but its $8.23B value still depends on regulatory progress and future commercial deployment. The uranium threat supports the strategic case for domestic fuel. It does not itself create revenue. A reversal in trade rhetoric could therefore unwind part of Tuesday's gain.
Sources: Yahoo Finance close and volume; Oklo Q2 2026 Form 10-Q; Oklo Groves first-criticality release; Reuters and AP trade reporting; S&P Global analyst compilation. All market figures as of August 25, 2026, 16:00 EDT.
Standard Nuclear Shares Climb 15% as First Quarterly Results Approaches
Shares of Standard Nuclear Inc. surged 14.7% on Tuesday, with investors anticipating the nuclear-fuel firm's first quarterly results since its listing in July. By 15:10 EDT, the stock was up $1.76 at $13.70, with 1.25 million shares changing hands.
NYSE: STDN · earnings setup
Standard Nuclear: the market is pricing backlog conversion
Market snapshot
Aug. 25, 2026 · 15:10 EDT
Aug. 25, 2026 · 15:10 EDT
Share price
$13.70
+$1.76 · +14.70%
Market value
$2.20B
≈$283M added today
Volume
1.25M
1.10× three-month average
Intraday range
$12.44–$14.90
High matched 52-week peak
The valuation bridge
Tuesday's market-value gain alone equals 4.35× funded backlog and 476× first-quarter revenue. Wednesday's report must show how signed work reaches the income statement.
Funded backlog: $65MContract options: $157MContingent backlog: $23MTotal disclosed: up to $245M
Price vs. sell-side range
$16.00
Average target · 7 ratings
Low $11 · current $13.70 · high $20
Financial baseline
| Metric | Q1 2026 / Mar. 31 | Read-through |
|---|---|---|
| Revenue | $0.594M | +57% year on year |
| Cost of revenue | $5.01M | Scale not yet economic |
| Net loss | -$7.71M | Early-stage spending |
| Cash | $124.9M | Before $150M IPO |
| Funded backlog | $65M | Binding work |
Analyst recommendations
| Firm | Rating | Target |
|---|---|---|
| RBC Capital | Outperform | $11 |
| BofA Securities | Buy | $15 |
| Stifel | Buy | $16 |
| Barclays | Overweight | $17 |
| Evercore ISI | Outperform | $17 |
| Goldman Sachs | Buy | $18 |
Initiations dated Aug. 10, 2026. Current price is above RBC's target.
Price and catalyst sequence
price path, directionalcatalyst
Next 42 hours
Q2 results
First report as a public company
First report as a public company
Investor call
Backlog, revenue and capacity focus
Backlog, revenue and capacity focus
Radiant agreement
Binding supply of multiple metric tons of TRISO fuel through 2031 for Radiant's one-megawatt Kaleidos microreactors.
Contract value was not disclosed. Delivery timing depends on reactor deployment and fuel availability.
Risk monitor
- Backlog may not convert into profitable revenue.
- Customers must obtain enriched uranium, including HALEU.
- Advanced-reactor schedules and approvals can slip.
- At $13.70, upside to the $16 average target is about 16.8%.
Sources: Standard Nuclear investor relations and SEC filings; Reuters; Yahoo Finance market data; S&P Global analyst data via Stock Analysis. Market figures timestamped Aug. 25, 2026, 15:10 EDT. Historical financials are through Mar. 31, 2026.
CRISPR Therapeutics Shares Advance 5.8% Ahead of CTX310 Results Release
Shares of CRISPR Therapeutics AG rose 5.8% on Tuesday, increasing its market capitalisation by roughly $319 million ahead of new CTX310 clinical results.
NASDAQ: CRSP · Stock move
CRISPR Therapeutics
CTX310 durability data becomes the next valuation test
Market data: Aug. 25, 2026, 12:38:56 EDT
U.S. regular session · Prices intraday
U.S. regular session · Prices intraday
Share price
$60.38
▲ $3.30 · +5.79%
Market cap
$5.84B
96.69M shares outstanding
Value added today
≈$319M
$3.30 × 96.69M shares
Citizens target
$80
+32.5% · ≈$7.74B implied cap
Intraday range and reference levels
The $80 target sits above the displayed 52-week high. Levels as of 12:38:56 EDT.
Balance-sheet and earnings frame
| Cash + marketable securities | $2.364B |
| Cash as share of market cap | 40.5% |
| Q2 revenue | $10.2M |
| Q2 R&D expense | $67.2M |
| Q2 net loss | $91.2M |
| CASGEVY Q2 global revenue | $76M |
Company data for quarter ended June 30, 2026; CASGEVY revenue is global product revenue reported by CRISPR.
Analyst map
| Firm | Latest action | Rating | Target | Implied return |
|---|---|---|---|---|
| Citizens | Aug. 25 | Market Outperform | $80 | +32.5% |
| Goldman Sachs | Aug. 10 | Hold | $55 | −8.9% |
| Bank of America | Aug. 5 | Buy | $82 | +35.8% |
| Morgan Stanley | Aug. 4 | Hold | $60 | −0.6% |
| Piper Sandler | Aug. 4 | Buy | $110 | +82.2% |
Google Finance displayed 13 analysts: eight Buy, five Hold and no Sell; average target $74.33. Implied returns use $60.38.
Catalyst clock
Aug. 25 · 12:38:56 EDTCRSP +5.79%; intraday high $61.55.
Aug. 28 · 16:30 CEST · MunichLate-breaking ESC presentation: durability of CTX310 effects.
Second half 2026Broader Phase 1b CTX310 update expected.
What the price is discounting
A durable ANGPTL3 response could add an in-vivo cardiovascular franchise beside CASGEVY. Tuesday's move capitalized that possibility before the data.
Risk check
CTX310 is early-stage. Small cohorts, safety findings or weaker durability could erase the move. Clinical value remains distinct from commercial value.
Investor bridge
$319 million gained versus $2.364 billion of liquidity. The stock's one-day market-value increase equals roughly 13.5% of reported cash and securities. Citizens' $80 target adds another $1.90 billion of implied equity value from the midday base. The August 28 data therefore tests whether investors will assign meaningful value to CTX310 before later-stage evidence.
Sources: CRISPR Therapeutics Q2 2026 business update; Google Finance; Citizens research note reported by Investing.com. Calculations may differ slightly because market capitalization and shares outstanding are rounded.
Supermicro Shares Climb 9% After Cisco Unveils October AI-Factory Sales Program
Super Micro Computer shares climbed 8.63% to $38.21 as of 11:31 EDT. The increase came after news of a distribution deal that integrates its rack-scale AI systems into Cisco’s secure factory framework. The stock’s advance boosted its market capitalization by about $1.96 billion.
NASDAQ: SMCI · Catalyst dashboard
Supermicro’s Cisco channel adds validation before revenue
Market snapshot: August 25, 2026, 11:31 EDT · U.S. regular session
Share price
$38.21
Up 8.63% from a $35.17 prior close.
Equity value
$24.71B
About $1.96B added during the move.
Volume
23.47M
Shares traded by 11:31 EDT on August 25.
Forward P/E
8.81×
Versus 22.68× for Dell and 21.50× for Cisco.
Revenue scale: actuals and fiscal 2027 guidance
The $68.5 billion midpoint implies 75.4% growth. Cisco’s October availability is a channel catalyst; no order value has been disclosed.
Q4 sales +93.2% YoYQ4 gross margin 17.5%New orders >$60B
Analyst positioning
Consensus: Hold · Average target $42.38 · Implied upside 10.9% from $38.21.
Comparable market snapshot
| Company | Price | Daily move | Market value | Forward P/E |
|---|---|---|---|---|
| Super Micro Computer (NASDAQ: SMCI) | $38.21 | +8.63% | $24.71B | 8.81× |
| Dell Technologies (NYSE: DELL) | $453.27 | +4.64% | $292.88B | 22.68× |
| Cisco Systems (NASDAQ: CSCO) | $110.97 | +0.67% | $437.38B | 21.50× |
Prices and valuation metrics: StockAnalysis snapshots at 11:30–11:31 EDT, August 25, 2026. SMCI outperformed the equal-weight daily move of Dell and Cisco by about 6.0 percentage points.
Catalyst path
Aug. 25
Cisco announces Supermicro liquid- and air-cooled compute for its Secure AI Factory with NVIDIA.
October
Cisco plans to begin offering Supermicro rack-scale compute to customers.
Next report
Investors test the $14.5–$15.5 billion fiscal first-quarter sales guide against bookings and delivery capacity.
Investor bridge
Cisco supplies distribution and enterprise validation. Supermicro supplies dense rack-scale compute and liquid cooling. The commercial link is direct, but not yet quantified: an October product path can widen customer access, while revenue depends on orders, pricing, delivery and margin.
| Q4 FY2026 sales | $11.1B | +93.2% YoY |
| Q4 FY2026 gross margin | 17.5% | +8.0 points YoY |
| Q1 FY2027 sales guide | $14.5–$15.5B | Midpoint +34.9% vs. Q4 |
| FY2027 sales guide | $65–$72B | +66.4% to +84.3% |
Risk monitor
Cisco disclosed no committed orders, pricing or margin. Taiwan’s August 24 server-export case adds compliance scrutiny: prosecutors allege 74 of 130 B300 systems reached China through indirect routes, while customs stopped 56. Supermicro says it is not an investigation target and is not accused of wrongdoing.
Sources: Cisco, Supermicro results, Reuters, StockAnalysis market data and analyst consensus. Time-sensitive market figures are stamped August 25, 2026, 11:30–11:31 EDT.
TechStock² Updates
